Thoracic Oncology

  • 1.  Zenocutuzumab administration

    Posted 21 days ago

    Hi all,

    Has anyone started using zenocutuzumab? There are different recommendations for infusion duration between the eNRGy1 study and FDA approval - eNRGy1 infused over 4 hours for first dose and then dropped to 2 hours for subsequent doses if no IRR Grade > 2, while FDA approved as 4 hours and does not mention reducing the infusion time. It seems reasonable to me to reduce the administration time for subsequent doses given the low rates of IRRs, but I was curious how others have implemented this or if anyone has further insight?

    Thanks in advance!

    Cami



    ------------------------------
    Cami Andreini, PharmD, BCOP, CPP
    Duke University Hospital
    cla54@duke.edu
    ------------------------------


  • 2.  RE: Zenocutuzumab administration

    Posted 17 days ago

    We haven't actually given this commercially yet, only on trial, which was the 4 hours for first dose and 2 hours for subsequent doses. The patients we treated tolerated the 2 hours, so agree it's odd the labeling doesn't address this!



    ------------------------------
    Courtney Cavalieri PharmD, BCOP
    Clinical Oncology Pharmacist
    Huntsman Cancer Institute at the University of Utah
    ------------------------------



  • 3.  RE: Zenocutuzumab administration

    Posted 15 days ago

    We have given it (not commercially, but as single IND), and we followed the prescribing information of 4-hours administration to be more conservative. No infusion reactions were observed. As you mentioned, hopefully the 2-hours infusion makes it into the PI as time goes on



    ------------------------------
    Andy Hui, PharmD BCPS
    Oncology Clinical Pharmacy Specialist
    Jersey Shore University Medical Center
    Hackensack Meridian Health Network
    ------------------------------

    Original Message


Related Content